Catalent Unable to File Annual Report on Time

(Reuters) – Catalent (NYSE:CTLT) announced on Friday that it was unable to file its annual report with regulators on time due to needing additional time to complete “certain processes”.

The contract drug manufacturer had been expected to file the report on August 29.

The company is currently awaiting the closure of the $16.5 billion takeover deal signed in February by Novo Holdings, which has a controlling interest in Danish drugmaker Novo Nordisk (NYSE:NVO).

Catalent anticipates the deal will close towards the end of the year.

Catalent specializes in fill-finish work, which includes the filling and packaging of syringes and injection pens in sterile conditions, notably for Novo Nordisk’s blockbuster drug Wegovy.

In May, the U.S. Federal Trade Commission requested more information regarding the deal after Novo Holdings prefiled an application seeking the antitrust agency’s approval.

On Thursday, the company surpassed analysts’ revenue estimates for the fourth quarter, aided by its biologics segment that develops and manufactures cell and gene therapies.